Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE CYSTO versus OXILAN 350.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE CYSTO versus OXILAN 350.
HYPAQUE-CYSTO vs OXILAN-350
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HYPAQUE-CYSTO (diatrizoate meglumine) is a radiopaque contrast agent that absorbs x-rays, providing contrast in radiographic imaging. It acts as an iodinated contrast medium.
Iodinated contrast medium that attenuates X-rays due to its iodine content, enhancing vascular and tissue contrast during imaging. It distributes in extracellular fluid and is freely filtered by glomeruli.
Intravesical instillation: 100-300 mL of 30% solution for retrograde cystourethrography; single administration.
Intravenous: 0.5–2 mL/kg (350 mg I/mL) for CT imaging; maximum 200 mL total. Intra-arterial: 0.3–1.5 mL/kg per injection; maximum 200 mL per procedure.
None Documented
None Documented
Terminal elimination half-life: 1.5–2.5 hours (normal renal function). Prolonged in renal impairment.
Terminal elimination half-life: 2 hours (normal renal function); prolonged in renal impairment (up to 24 hours in severe impairment).
Renal excretion via glomerular filtration: >95% unchanged within 24 hours. Fecal excretion: <5%.
Renal: >90% unchanged drug within 24 hours; Biliary/fecal: <2%
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent